Ad spend helps Crestor outpace Lipitor growth: Bloomberg.com

Share this article:
AstraZeneca outspent rivals Pfizer and Merck by 30% on consumer advertising for Crestor, helping the drug become the fastest-growing cholesterol treatment, Bloomberg.com reported. AstraZeneca spent $166.5 million on Crestor TV, print and radio promotion to consumers in 2006 to November, the Web site reported, citing data from Nielsen Monitor-Plus. That number compares with $128 million spent by Merck on Vytorin and $104 million spent by Schering-Plough on Zetia. Crestor is taking Pfizer’s Lipitor, the top-selling cholesterol-lowering treatment and the world’s best-selling prescription medicine, with 2006 global sales of $12.8 billion. Pfizer spent approximately $18 million on consumer advertising for Lipitor in 2006 to November, with sales gaining 15% in the third quarter. During the third quarter of 2006, Crestor sales rose 64% to outpace Vytorin, according to Bloomberg.com.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...